Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Total Carbon Neutrality Ventures' international outlook has eased the switch to remote working somewhat, and opportunities are available for careful investors.
Startups with fewer than 500 employees will be able to apply for loans of up to $10m from the US government's $350bn Paycheck Protection Program.
Cowen and European Investment Bank added $52m to a $130m first tranche closed by the AbbVie and Pfizer-backed kidney injury drug developer in July.
The WuXi-backed investment firm returned for a series B2 round that will support phase 1/2 trials for iTeos Therapeutics' oncology therapies.
Autoimmune disease drug developer Pandion Therapeutics closed a series B round co-led by Access Biotechnology and backed by Roche Venture Fund and SR One.
CapitalG returned for a late-stage round that pushed Collibra’s total funding beyond $345m and boosted its valuation to $2.3bn.
The Parkinson's disease therapy developer closed the series A funding less than four months after a Eurofarma-backed seed round.